حول الموقع:

اسم النطاق - tsillc.ae

عنوان الموقع - Default Page for new sites hosted on EIM servers

اذهب إلى الموقع - Default Page for new sites hosted on EIM servers

موقع جيو

البلد الموقع - United Arab Emirates

المدينة / البلدة - Dubai

مزود - Emirates Telecommunications Group Company (etisalat Group) Pjsc

Site Logo

عنوان IP:

5.195.197.78

خوادم اسم المجال:

ns4.etisalatdomains.ae ns3.etisalatdomains.ae ns1.etisalatdomains.ae ns2.etisalatdomains.ae

كل السجلات:

☆ tsillc.ae. 3066 IN TXT "v=spf1 include:_spf3.emirates.net.ae -all"
☆ tsillc.ae. 21066 IN NS ns1.etisalatdomains.ae.
☆ tsillc.ae. 21066 IN NS ns2.etisalatdomains.ae.
☆ tsillc.ae. 21066 IN NS ns4.etisalatdomains.ae.
☆ tsillc.ae. 21066 IN NS ns3.etisalatdomains.ae.
☆ tsillc.ae. 21066 IN MX 20 imailv2.emirates.net.ae.
☆ tsillc.ae. 21066 IN MX 10 imailv.emirates.net.ae.
☆ tsillc.ae. 21066 IN A 5.195.197.78
☆ tsillc.ae. 21066 IN SOA a2e-ib-dns-gm.etisalat.ae. users_ics.etisalat.ae. 2020110336 10800 3600 2419200 900

Brief facts about tsillc:

Thrombolytic Science, LLC is a private, clinical stage biopharmaceutical company that was founded in 2006 based on the research of Harvard scientist Victor Gurewich into the potential use of prourokinase to break up blood clots. Gurewich co-founded the company and the founding CEO is business person Alexis Wallace. TSI's lead drug candidate is a synergistic sequential dual therapy combination of mutant prourokinase and a small dose of tPA [Tissue Plasminogen Activator]. TSI is developing its dual therapy as a potential treatment for conditions caused by blood clots, initially for ischemic stroke and heart attacks. The company completed a Phase I trial in The Netherlands in 2017. It started Phase II in 2018. The company raised $8 million by 2012 mostly from an undisclosed angel investor.

Privately held companies based in Massachusetts

Companies based in Cambridge, Massachusetts

Biotechnology companies of the United States